Title:
OCTS TECHNOLOGY-BASED PROSTATE CANCER CAR-T THERAPEUTIC VECTOR, CONSTRUCTION METHOD THEREFOR, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2018/218875
Kind Code:
A1
Abstract:
Provided is a prostate cancer CAR-T therapeutic vector targeting both PSMA and PDL1, comprising a lentiviral backbone plasmid, a human EF1α promoter, a double targeting chimeric receptor domain, and a PDL1 single-chain antibody. The double targeting chimeric receptor domain comprises a CD8 leader chimeric receptor signal peptide, a PSMA single-chain antibody light chain variable region, a PSMA single-chain antibody heavy chain variable region, a PDL1 single-chain antibody light chain variable region, a PDL1 single-chain antibody heavy chain variable region, an inner-antibody hinge, an inter-single-chain antibody hinge, a CD8 chimeric receptor hinge, a CD8 chimeric receptor transmembrane region, a TCR chimeric receptor T cell activation domain, and a chimeric receptor costimulatory factor region. Also provided are a method for constructing said vector and use thereof in the preparation of a medicament for treating prostate cancer.
Inventors:
QI WEI (CN)
YU LEI (CN)
KANG LIQING (CN)
LIN GAOWU (CN)
YU ZHOU (CN)
YU LEI (CN)
KANG LIQING (CN)
LIN GAOWU (CN)
YU ZHOU (CN)
Application Number:
PCT/CN2017/110664
Publication Date:
December 06, 2018
Filing Date:
November 13, 2017
Export Citation:
Assignee:
SHANGHAI UNICAR THERAPY BIO MEDICINE TECH CO LTD (CN)
International Classes:
C12N15/867; A61K35/17; A61P35/00; C12N5/10; C12N15/62
Domestic Patent References:
| WO2016149578A1 | 2016-09-22 |
Foreign References:
| CN107164410A | 2017-09-15 | |||
| CN105874061A | 2016-08-17 | |||
| US20130280220A1 | 2013-10-24 | |||
| CN105602992A | 2016-05-25 |
Other References:
HILLERDAL, V.: "Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer", BIODRUGS, vol. 29, no. 2, 10 April 2015 (2015-04-10), pages 75 - 89, XP055379652, ISSN: 1179-190X, DOI: 10.1007/s40259-015-0122-9
SERGANOVA, I.: "Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade", MOLECULAR THERAPY ONCOLYTICS, vol. 4, 17 March 2017 (2017-03-17), pages 41 - 54, XP055632906, ISSN: 2372-7705, DOI: 10.1016/j.omto.2016.11.005
JASPERS, J.E.: "Development of CAR T cells designed to improve antitumor efficacy and safety", PHARMACOLOGY & THERAPEUTICS, vol. 178, 22 March 2017 (2017-03-22), pages 83 - 91, XP085202015, ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2017.03.012
SERGANOVA, I.: "Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade", MOLECULAR THERAPY ONCOLYTICS, vol. 4, 17 March 2017 (2017-03-17), pages 41 - 54, XP055632906, ISSN: 2372-7705, DOI: 10.1016/j.omto.2016.11.005
JASPERS, J.E.: "Development of CAR T cells designed to improve antitumor efficacy and safety", PHARMACOLOGY & THERAPEUTICS, vol. 178, 22 March 2017 (2017-03-22), pages 83 - 91, XP085202015, ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2017.03.012
Attorney, Agent or Firm:
SHANGHAI HONGJING INTELLECTUAL PROPERTY AGENCY (GENERAL PARTNERSHIP) (CN)
Download PDF: